AUTHORS
Rajshekhar Chakraborty, MD, Anita D'Souza Jr, MD2, Omar K Siddiqi, MD3, Shikun Wang, PhD4, Divaya Bhutani, MD5, Michael Sang Hughes, MD6, Priyesha Sanjay Patel, BDS7, Sachin Lakhotia8, Margaret Doyle, MSc, BSPharm, PharmD9, Sanjay Vara10, Jordan Schecter, MD, BS11, Mansi Ramesh Shah, MD12, Vaishali Sanchorawala, MD13, Suzanne Lentzsch, MD, PhD14
AFFILIATIONS
1 Columbia University Irving Medical Center, New York, New York, United States
2 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
3 Boston Medical Center, Boston, Massachusetts, United States
4 Columbia University Irving Medical Center, New York, New York, United States
5 Columbia University Irving Medical Center, New York, New York, United States
6 Columbia University Irving Medical Center, New York, New York, United States
7 Columbia University Irving Medical Center, New York, New York, United States
8 Columbia University Irving Medical Center, New York, New York, United States
9 Johnson & Johnson, Raritan, New Jersey, United States
10 Johnson & Johnson, Raritan, New Jersey, United States
11 Johnson & Johnson, Raritan, New Jersey, United States
12 Rutgers Cancer Institute, New Brunswick, New Jersey, United States
13 Boston Medical Center, Boston, Massachusetts, United States
14 Columbia University Irving Medical Center, New York, New York, United States
ABSTRACT
Background: Daratumumab-CyBorD has transformed frontline therapy for AL amyloidosis, yet nearly half of patients are unable to achieve complete hematologic response (heme-CR)—a benchmark strongly associated with organ response and survival—by 6 months. Teclistamab, a BCMA×CD3 bispecific antibody, combined with daratumumab, has demonstrated unprecedented efficacy and manageable safety profile in relapsed/refractory myeloma (MajesTEC-3), providing rationale for evaluating this combination as frontline therapy in AL amyloidosis, where deep and rapid hematologic response is critical to halting organ damage.
Methods: IMPACT-AL (NCT07110844) is a multicenter, single-arm, phase 2 trial enrolling previously untreated Mayo 2004 stage I-IIIa patients with measurable hematologic disease (dFLC≥5 mg/dL and/or serum M-protein≥0.5 g/dL), ECOG 0-2, and eGFR ≥20mL/min/1.73 m² across 3 US sites. Key exclusions include NT-proBNP>8,500 pg/mL, NYHA IIIb/IV, and concomitant multiple myeloma. Patients receive subcutaneous teclistamab (standard step-up dosing) plus daratumumab-hyaluronidase for a fixed-duration of six 28-day cycles, with dexamethasone omission permitted from cycle 2 per investigator discretion.
The primary endpoint is heme-CR rate by 6 months. Key secondary endpoints include MRD-negativity (serum FLC mass spectrometry and bone marrow flow cytometry, sensitivity 10-5), safety (CRS, ICANS, infections), and organ response. The trial used Simon’s optimal 2-stage design (p0=55%; p1=80%; α=0.1; power 80%), requiring >3 heme-CRs among the first 8 evaluable patients to proceed to stage 2 (total planned enrollment 25). We report on the pre-specified stage 1 interim analysis.
Results: As of June 2026, 11 patients were screened, with 2 screen failures (concurrent AL/ATTR amyloidosis and NT-proBNP>8,500 pg/mL), yielding 9 enrolled patients. One patient was deemed non-evaluable for the primary endpoint following a fatal treatment-emergent adverse event with hemorrhagic shock due to spontaneous liver rupture in cycle 1, adjudicated as unrelated to study treatments. Autopsy showed large disrupted subcapsular hematoma of the right lobe of liver, with microscopic examination showing extensive amyloid deposition in the sinusoids and vasculature.
Among 9 enrolled patients, median age was 70 years, 4/9 (44.4%) were females, 5/9 (55.6%) were White, and AL isotype was lambda in 7/9 (77.8%). Median dFLC at baseline was 24.85 mg/dL (range, 2.98-59.73), median NT-proBNP was 1,257 pg/mL (range, 50-11,371), and median eGFR was 51 mL/min/1.73m2 (range, 34-90). Cardiac involvement was present in 5/9 patients (55.6%) and renal involvement in 6/9 (66.7%), with 4/9 patients (44.4%) classified as Mayo 2004 stage IIIa at screening. Among 5 patients with cardiac involvement, the median global longitudinal strain was -7.4% (range, -4.2 to -8.2%).
Prophylactic tocilizumab (8 mg/kg) prior to the first step-up dose of teclistamab was administered in 6/9 patients (66.7%). Treatment-related adverse events (AEs) thus far included cytokine release syndrome (n=2, both grade 1, and in patients who did not receive prophylactic tocilizumab), sepsis due to Staphylococcus aureus bacteremia (n=1, grade 3), adenovirus upper respiratory infection (n=1, grade 2), Campylobacter jejuni infection (n=1, grade 2), lymphopenia (n=5, with 4 grade≥3), and rash (n=1, grade 2). None of the patients developed immune effector cell-associated neurotoxicity syndrome.
Among 6 patients evaluable at C2D1, all achieved at least a hematologic VGPR (dFLC<4 mg/dL) as per consensus response criteria (≥VGPR rate of 100%; exact 95% confidence interval, 54–100%). Furthermore, 5/9 patients achieved dFLC<1 mg/dL at C1D15 and all 6 evaluable patients had done so by C2D1. Data on 6-month heme-CR and organ response rates for the 8 evaluable patients will mature by late 2026 and will be presented at the meeting.
Conclusions: Teclistamab-Daratumumab achieved universal heme-VGPR within the first treatment cycle in newly diagnosed AL amyloidosis, with a favorable safety profile. These stage 1 interim results support the promise of a bortezomib and cyclophosphamide-sparing frontline regimen.
Funding/Acknowledgement: This study was funded by Johnson & Johnson Innovative Medicine and Stand Up To Cancer (SU2C).
DISCLOSURES
Rajshekhar Chakraborty, MD: Alexion - Honoraria; Adaptive Biotechnologies - Honoraria; Pfizer - Honoraria; Janssen - Honoraria; Sanofi - Honoraria; AbbVie - Research Funding; Genentech - Research Funding; Sanofi - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Alexion - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony); Adaptive Biotechnologies - Consultancy (Includes expert testimony); Sanofi Pasteur - Consultancy (Includes expert testimony)